1.96
-0.01 (-0.51%)
| Penutupan Terdahulu | 1.97 |
| Buka | 1.99 |
| Jumlah Dagangan | 28,650 |
| Purata Dagangan (3B) | 66,780 |
| Modal Pasaran | 696,168,640 |
| Harga / Pendapatan (P/E Ke hadapan) | 53.48 |
| Harga / Jualan (P/S) | 0.830 |
| Harga / Buku (P/B) | 0.880 |
| Julat 52 Minggu |
| Margin Keuntungan | -26.26% |
| Margin Operasi (TTM) | -9.91% |
| EPS Cair (TTM) | -0.690 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 52.48% |
| Nisbah Semasa (MRQ) | 2.03 |
| Aliran Tunai Operasi (OCF TTM) | 34.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -90.11 M |
| Pulangan Atas Aset (ROA TTM) | -2.42% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Evotec SE | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.17 |
|
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Institusi | 2.56% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Optiver Holding B.V. | 31 Mar 2026 | 283,576 |
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Snowden Capital Advisors Llc | 31 Mar 2026 | 24,409 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |